Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
- 30 June 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 56 (6), 1343-1350
- https://doi.org/10.1016/j.jhep.2012.01.009
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Targeted Therapies for Hepatocellular CarcinomaGastroenterology, 2011
- MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517aGastroenterology, 2011
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Molecular targeted therapies in hepatocellular carcinomaJournal of Hepatology, 2008
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysisThe Lancet Oncology, 2008
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomyBritish Journal of Cancer, 2008
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006